Danaher Corporation (NYSE:DHR) Shares Sold by Callan Family Office LLC

Key Points

• Callan Family Office LLC reduced its stake in Danaher Corporation by 16.4%, owning 9,316 shares worth approximately $1.91 million after selling 1,831 shares in the first quarter.
• Danaher reported a quarterly earnings per share (EPS) of $1.80, surpassing estimates by $0.16, with a net revenue of $5.94 billion.
• Analysts have given Danaher a rating of "Moderate Buy" with an average price target of $247.61, while several firms have adjusted their price objectives for the stock in recent weeks.

Callan Family Office LLC decreased its stake in shares of Danaher Corporation (NYSE:DHR - Free Report) by 16.4% during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 9,316 shares of the conglomerate's stock after selling 1,831 shares during the period. Callan Family Office LLC's holdings in Danaher were worth $1,910,000 as of its most recent SEC filing.

Several other hedge funds have also bought and sold shares of DHR. GHP Investment Advisors Inc. lifted its position in Danaher by 396.0% during the first quarter. GHP Investment Advisors Inc. now owns 124 shares of the conglomerate's stock valued at $25,000 after purchasing an additional 99 shares during the period. Heck Capital Advisors LLC bought a new position in Danaher during the fourth quarter valued at approximately $27,000. Sierra Ocean LLC increased its holdings in Danaher by 116.9% during the first quarter. Sierra Ocean LLC now owns 141 shares of the conglomerate's stock valued at $29,000 after buying an additional 76 shares during the last quarter. Smallwood Wealth Investment Management LLC purchased a new stake in Danaher during the first quarter valued at approximately $31,000. Finally, Dunhill Financial LLC increased its holdings in Danaher by 68.4% during the first quarter. Dunhill Financial LLC now owns 165 shares of the conglomerate's stock valued at $34,000 after buying an additional 67 shares during the last quarter. Institutional investors own 79.05% of the company's stock.

Danaher Stock Up 0.3%

NYSE DHR traded up $0.62 during trading on Friday, reaching $210.84. 3,210,213 shares of the company's stock traded hands, compared to its average volume of 4,658,279. The company's 50 day simple moving average is $199.94 and its two-hundred day simple moving average is $199.71. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.62 and a quick ratio of 1.22. Danaher Corporation has a 12-month low of $171.00 and a 12-month high of $279.90. The firm has a market cap of $150.97 billion, a price-to-earnings ratio of 44.86, a price-to-earnings-growth ratio of 2.94 and a beta of 0.73.

Danaher (NYSE:DHR - Get Free Report) last issued its quarterly earnings data on Tuesday, July 22nd. The conglomerate reported $1.80 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.64 by $0.16. Danaher had a net margin of 14.21% and a return on equity of 10.70%. The firm had revenue of $5.94 billion for the quarter, compared to the consensus estimate of $5.83 billion. During the same quarter in the previous year, the firm earned $1.72 EPS. The company's quarterly revenue was up 3.4% compared to the same quarter last year. As a group, sell-side analysts forecast that Danaher Corporation will post 7.63 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of analysts have commented on the stock. The Goldman Sachs Group reduced their target price on shares of Danaher from $260.00 to $240.00 and set a "neutral" rating for the company in a report on Wednesday, April 23rd. Guggenheim restated a "buy" rating and set a $250.00 target price on shares of Danaher in a research report on Wednesday, July 23rd. Argus dropped their target price on shares of Danaher from $260.00 to $240.00 in a research report on Wednesday, April 23rd. UBS Group dropped their target price on shares of Danaher from $240.00 to $225.00 and set a "buy" rating for the company in a research report on Wednesday, July 23rd. Finally, Wall Street Zen upgraded shares of Danaher from a "hold" rating to a "buy" rating in a research report on Friday, June 27th. Three equities research analysts have rated the stock with a hold rating and eighteen have given a buy rating to the stock. According to data from MarketBeat.com, Danaher presently has an average rating of "Moderate Buy" and a consensus target price of $247.61.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.